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How should a DEXA scan 
be used to evaluate
bisphosphonate therapy 
for osteoporosis?  
■ EVIDENCE-BASED ANSWER
If bone density is evaluated after initiating bispho-
sphonate drug therapy, it should be tested no ear-
lier than 2 years (strength of recommendation
[SOR]: B, based on case series of dual energy x-
ray absorptiometry [DEXA] scanning precision
and bisphosphonate efficacy). Currently no
prospective, randomized trials investigate the
impact of bone density follow-up testing on osteo-
porotic patients receiving bisphosphonate therapy. 
■ EVIDENCE SUMMARY
Testing the effectiveness of therapy for osteoporo-
sis by measuring changes in bone mineral density
(BMD) is difficult because changes are often small
and occur slowly, and a decrease in BMD does not
necessarily mean treatment failure. Testing
patients after starting bisphosphonate therapy
has been part of many drug trials to assess the
effectiveness of therapy. Follow-up testing in clin-
ical practice has not been the focus of a prospec-
tive trial and therefore remains controversial.1
DEXA is considered the gold standard because
it is the most extensively validated test for pre-
dicting fracture outcomes.2 Understanding the
rate of bone density response to therapy, and the
precision error of DEXA, helps to determine mon-
itoring intervals. The larger the responses in
BMD to therapy and the more precise the DEXA
scan result, the shorter the period between test-
ing in which clinically relevant differences can be
found. Precision error rates are estimated at <1%
for the anterior-posterior spine and 1% to 2% for
the hip.3 The BMD change after the initiation of
treatment must escape the precision error of the
testing device or exceed the least significant
change (LSC) value.4 The LSC—roughly analo-
gous to a 95% confidence interval—is 2.8 times
the precision error of the test on a specific
machine and site of measurement. If the precision
error for DEXA of the femoral neck BMD is 2%,
then the LSC is 5.6%.5 Changes in BMD of
<2%–4% in the vertebrae and 3% to 6% at the hip
could be due to inherent measurement error.6
A clinician must also understand the antici-
pated response to the prescribed therapy. It is not
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in the first year normalized in the second year.10 A
second analysis showed that when women were
divided into 8 groups, the group with the greatest
increase in BMD in the first year (10.4%) also had
the greatest decrease (1.0%) in year 2. In addi-
tion, the group with the greatest decrease in year
1 (6.6%) had the greatest increase in year 2
(4.8%). The variability in response among the 8
groups was approximately 17% (+10.4% and
–6.6%) in year 1 and narrowed to a 6% difference
in year 2 This regression to the mean leads to a
normalization of bone density results.11,12 This
patient variability in BMD response to the pre-
scribed therapy should be considered when decid-
ing to retest. 
In summary, limitations in DEXA precision
mean any changes in BMD of less than 5.6% at
the femoral neck may be due to measurement
error, and BMD response to bisphosphonates
vacillates in the first few years of use but can be
clinically useful to retest BMD before a therapy
would have time to affect bone turnover.
Alendronate and risedronate increase lumbar
spine BMD by 5% to 7% and hip BMD by 3% to
6% when used for approximately 3 years.7,8 These
increases in BMD are associated with 30% to
50% reductions in vertebral and hip fractures.6
Alendronate continues to increase BMD: follow-
ing 10 years of treatment, it increased BMD by
13.7% in the lumbar spine, 6.7% in the total hip,
and 5.4 % in the femoral neck.9
Frequent testing, as seen in bisphosphonate
clinical trials, demonstrates the phenomenon of
regression to the mean. One analysis of the FIT
trial, which compared alendronate with placebo
in postmenopausal women with low BMD and at
least 1 vertebral fracture, focused on the early
evaluation of BMD. The study found a high
degree of variability in BMD when tested after 1
year of treatment. This wide variety of response
Bone mineral density in osteoporosis
F I G U R E
DEXA scanning is useful 
if its limitations are understood
Imprecision is a reality with the DEXA scan.
Clinical experience has shown that, for
patients receiving biphosphonate therapy to
increase bone mineral density (BMD) in the
femoral neck, any change in BMD of less
than 5.6% may be due to measurement
error and should not necessarily prompt a
change in treatment. BMD response to 
bisphosphonates vacillates in the first few
years of use but can be expected to
increase femoral neck BMD by 3% to 6%
over 3 years. If serial DEXA scanning is
made part of the management plan, it
should be considered no sooner than 2 to 3
years following the start of therapy.
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■ RECOMMENDATIONS FROM
OTHERS
Guidelines on monitoring the clinical response to
osteoporosis therapy with DEXA are available
from numerous groups (Table). In clinical prac-
tice, it is common for a BMD difference of 3% to
5% at the spine or 4% to 6 % at the hip to be con-
sidered clinically significant.13
Peter G. Koval, PharmD, BCPS, Lisa Easterling,
PharmD, Moses Cone Family Practice Residency, Greensboro,
NC; Dawn Pettus, PharmD, CPP, Greensboro AHEC,
Greensboro; Leslie Mackler, MSLS, Moses Cone Health
System Library, Greensboro
expected to increase femoral neck BMD 3% to
6% over 3 years. Therefore, if serial DEXA scan-
ning is preformed on patients prescribed bispho-
sphonate therapy, it should be considered no
earlier than 2 to 3 years after therapy begins.
When monitoring osteoporosis therapy, a BMD
change within the LSC should be interpreted as
“no change” and should not lead to changes in
patient management. If the BMD has decreased
beyond the LSC there is cause for concern and
reevaluation of diagnosis and treatment are
warranted.4
TA B L E
Recommendations on monitoring the clinical response 
to DEXA in osteoporosis therapy
Method used 
to formulate responses Recommendations for monitoring treatment 
Organization recommendation to anti-resorptive therapy
AHRQ Evidence Report Systematic review Advises against repeating bone density tests 
(Osteoporosis in within the first year of treatment. Insufficient 
Postmenopausal evidence to determine whether repeating tests 
Women)14 2 years after starting therapy is useful
American Association  Rating scheme Yearly for 2 years and if bone mass has 
of Clinical (Statement not rated) stabilized, follow-up measurements are
Endocrinologists13 recommended every 2 years
Canadian Panel of Not stated Repeat scan should be considered after 1 to 3 
Int’l Society for years if concerned about progressive bone loss 
Clinical Densitometry15 or with new intervention
Institute for Clinical Not stated Controversy exists as to whether follow-up testing 
Systems Improvement1 is necessary in all patients, but if performed, it 
should be done after 1 to 2 years of therapy
National Institute Expert consensus Monitoring has not been shown to improve 
of Health16 compliance. Physicians should not stop or
change therapies because of modest bone density loss
National Osteoporosis Expert consensus Recommended 1 to 2 years following initiation 
Foundation6 of therapy
North American Expert consensus Monitoring before 2 years of treatment would 
Menopause Society17 not be useful
Osteoporosis Society Not stated Suggests at least 1 follow-up measurement is 
of Canada18 necessary. Central bone densitometry 1 to 2 
years following initiation of bisphosphonate therapy.
For patients receiving hormone therapy, repeat 
BMD is recommended at 2 to 4 years
University of Michigan19 Evidence rating scheme For most persons an interval of >2 years between
DEXAs provides the most meaningful information
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■ CLINICAL COMMENTARY
If follow-up is needed, rescan in 2 to 3 years
Rates of vertebral and hip fractures are signifi-
cantly reduced by alendronate and risedronate,
making them important in the prevention and
treatment of osteoporosis. Despite controver-
sies over the timing and necessity of monitoring
bisphosphonate therapy with DEXA scans, they
may be useful clinically if their limitations are
recognized. It is necessary to wait 2 to 3 years
to repeat the DEXA after initiating therapy to
account for the slow rate of change of bone den-
sity and compensate for the regression-to-the-
mean phenomenon seen in clinical trials.
If after 2 or 3 years the bone density remains
stable or has increased, reassurance can be
given that fracture risk has decreased. If bone
density has decreased more than the LSC, con-
sider the following questions. Is the medicine is
being taken first thing in the morning on an
empty stomach? Is weight-bearing exercise
performed routinely, tobacco avoided, and caf-
feine limited? Is the patient continuing ade-
quate calcium and vitamin D supplements? The
physician should also consider secondary caus-
es of osteoporosis, such as hyperthyroidism
and hyperparathyroidism. 
Ann B. Gotschall, MD, Baylor College of Medicine,
Houston, Tex
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